Potential conflict of interest: Dr. Lim consults for and received grants from Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, and Vertex. He received grants from Abbott, GlaxoSmithKline, Janssen, and Roche. He consults for Merck.
Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection
Article first published online: 29 JUL 2013
Copyright © 2013 by the American Association for the Study of Liver Diseases
Volume 58, Issue 2, pages 822–826, August 2013
How to Cite
Liapakis, A. and Lim, J. K. (2013), Impact of rapid point-of-care screening tests for the identification of chronic hepatitis C infection. Hepatology, 58: 822–826. doi: 10.1002/hep.26552
- Issue published online: 29 JUL 2013
- Article first published online: 29 JUL 2013
- Accepted manuscript online: 6 JUN 2013 04:34PM EST
- Manuscript Accepted: 23 APR 2013
- Manuscript Revised: 16 APR 2013
- Manuscript Received: 12 APR 2013
- 1Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins; 2003., , .
- 3World Health Organization on the Internet. 2012. WHO media center. Accessed Nov. 28 2012: http://www.who.int/mediacentre/factsheets/fs164/en/.
- 5IOM (Institute of Medicine). 2010. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press.
- 7CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR 2012;61(RR-4):1-32.
- 11Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-748., , , , , , et al.
- 12Dual oral therapy with NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or patients ineligible/intolerant to peginterferon/ribavirin. J Hepatol 2012;56(Suppl 2):S7;A14., , , , , , et al.
- 1412-week interferon-free regimen of ABT-450/R + ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 2012;56(Suppl 2):S549;A1399., , , , , , et al.
- 16CDC. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR 2003;52(No. RR-3).